Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M S Brose

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Journal of Medical Genetics|November 3, 2004
Germline CHEK2*1100delC mutations in breast cancer patients with multiple primary cancersJ Huang, S M Domchek, M S Brose, et al.
Genetic Testing|September 4, 2004
Characterization of two novel BRCA1 germ-line mutations involving splice donor sitesM S Brose, P Volpe, K Paul, et al.
Journal of Dental Research|January 12, 2011
Targeted inhibition of CD133+ cells in oral cancer cell linesM Damek-Poprawa, A Volgina, J Korostoff, et al.
Oncogene|September 7, 2010
The RET/PTC3 oncogene activates classical NF-κB by stabilizing NIKR J Neely, M S Brose, C M Gray, et al.
Journal of Medical Genetics|April 3, 2004
Absence of BRAF mutations in UV-protected mucosal melanomasR H Edwards, M R Ward, H Wu, et al.
The Journal of Clinical Endocrinology and Metabolism|April 17, 2013
Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trialR C Smallridge, J A Copland, M S Brose, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2019
Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation studyD S Hong, T M Bauer, J J Lee, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Journal of Medical Genetics|November 3, 2004
Germline CHEK2*1100delC mutations in breast cancer patients with multiple primary cancersJ Huang, S M Domchek, M S Brose, et al.
Genetic Testing|September 4, 2004
Characterization of two novel BRCA1 germ-line mutations involving splice donor sitesM S Brose, P Volpe, K Paul, et al.
Journal of Dental Research|January 12, 2011
Targeted inhibition of CD133+ cells in oral cancer cell linesM Damek-Poprawa, A Volgina, J Korostoff, et al.
Oncogene|September 7, 2010
The RET/PTC3 oncogene activates classical NF-κB by stabilizing NIKR J Neely, M S Brose, C M Gray, et al.
Journal of Medical Genetics|April 3, 2004
Absence of BRAF mutations in UV-protected mucosal melanomasR H Edwards, M R Ward, H Wu, et al.
The Journal of Clinical Endocrinology and Metabolism|April 17, 2013
Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trialR C Smallridge, J A Copland, M S Brose, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2019
Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation studyD S Hong, T M Bauer, J J Lee, et al.
Pageof 1